Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.

Critical Care Medicine Section, Department of Anesthesiology, Ochsner Medical Center, 1514 Jefferson Highway, New Orleans, LA 70121, USA.
Critical care research and practice 01/2012; 2012:290805. DOI: 10.1155/2012/290805
Source: PubMed

ABSTRACT The heme-protein soluble guanylyl cyclase (sGC) is the intracellular receptor for nitric oxide (NO). sGC is a heterodimeric enzyme with α and β subunits and contains a heme moiety essential for binding of NO and activation of the enzyme. Stimulation of sGC mediates physiologic responses including smooth muscle relaxation, inhibition of inflammation, and thrombosis. In pathophysiologic states, NO formation and bioavailability can be impaired by oxidative stress and that tolerance to NO donors develops with continuous use. Two classes of compounds have been developed that can directly activate sGC and increase cGMP formation in pathophysiologic conditions when NO formation and bioavailability are impaired or when NO tolerance has developed. In this report, we review current information on the pharmacology of heme-dependent stimulators and heme-independent activators of sGC in animal and in early clinical studies and the potential role these compounds may have in the management of cardiovascular disease.

1 Bookmark
  • New England Journal of Medicine 07/2013; 369(4):386-8. · 54.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Panax notoginseng (Burk.) F. H. Chen has been used traditionally for the treatment of cardiovascular diseases. Notoginsenoside Ft1 (Ft1) is a bioactive saponin from the leaves of Panax notoginseng. Experiments were designed to determine whether or not Ft1 is an endothelium-dependent vasodilator. Rat mesenteric arteries were suspended in organ chambers for the measurement of isometric tension during phenylephrine-induced contractions. The cyclic guanosine monophosphate (cGMP) level was assessed using enzyme immunoassay. The phosphorylation and protein expressions of endothelial nitric oxide synthase (eNOS), glucocorticoid receptors (GR), estrogen receptors beta (ERβ), protein kinase B (Akt) and extracellular signal-regulated kinase 1/2 (ERK1/2) were determined by Western blotting. The localization of GR and ERβ were determined by immunofluorescence staining. Ft1 caused endothelium-dependent relaxations, which were abolished by L-NAME (inhibitor of nitric oxide synthases) and ODQ (inhibitor of soluble guanylyl cyclase). Ft1 increased the cGMP level in rat mesenteric arteries. GR and ERβ were present in the endothelial layer and their antagonism by RU486 and PHTPP, respectively, inhibited Ft1-induced endothelium-dependent relaxations and phosphorylations of eNOS, Akt and ERK1/2. Inhibition of phosphoinositide-3-kinase (PI3K) by wortmannin and ERK1/2 by U0126 reduced Ft1-evoked relaxations and eNOS phosphorylation. Taken in conjunction, the present findings suggest that Ft1 stimulates endothelial GRs and ERβs with subsequent activation of the PI3K/Akt and ERK1/2 pathways in rat mesenteric arteries. This results in phosphorylation of eNOS and the release of NO, which activates soluble guanylyl cyclase in the vascular smooth muscle cells leading to relaxations.
    Biochemical pharmacology 01/2014; · 4.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Infusion reactions can be serious life threatening adverse events and have been associated with many drugs and biologic agents. Our objective was to report drugs associated with infusion reactions using two different data-mining methodologies. Methods: The Food and Drug Administration Adverse Event Reporting System (FAERS) was data-mined for drugs highly associated with infusion reactions. Drugs were included if there were >10 reported adverse events and if the Empirical Bayesian Geometric Mean (EBGM) score ≥ 2. Molecular Health’s MASE (Molecular Analysis of Side Effects) reports Proportional Reporting Ratios (PRR) for drugs highly associated with infusion reactions and was cross-referenced to improve detection sensitivity. Results: Using FAERS, the highest EBGM scores by class were reported as: pegloticase and α-1- antitrypsyn (enzymes), iron dextran and ferric gluconate (electrolytes and nutrients), infliximab and gemtuzumab (immunomodulators), and paclitaxel and oxaliplatin (antimetabolites). Using MASE, the highest PRR scores were reported as: idursulfase and galsulfase (enzymes), iron dextran and phytonadione (electrolytes and nutrients), gemtuzumab and infliximab (immunomodulators), mercaptopurine and azathioprine (antimetabolites). Amphotericin and vancomycin had the highest scores for the antimicrobial class for both FAERS and MASE. Conclusions: Using the two statistical methods EBGM and PRR, both specificity and sensitivity were preserved. However, neither system detected several drugs with established relationships to infusion reactions, including protamine and nitroglycerine. Reactions caused by these drugs were possibly underreported because the effects have been well established or due to evolution of administration with slower administration. We hope this analysis encourages further research into overlapping mechanisms for infusion reactions.
    Journal of Blood Disorders & Transfusion. 01/2014; 5:195.

Full-text (2 Sources)

Available from
May 31, 2014